Squarepoint’s First Tracks Biotherapeutics TRAX Stock Holding History

Squarepoint’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$322K	Buy	+9,074	New	+$354K	﹤0.01%	3720

Other funds holding TRAX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Squarepoint's TRAX Position: Q3 2026 in Review

Squarepoint opened a new position in First Tracks Biotherapeutics (TRAX) in Q3 2026: 9,074 shares worth $322K. The stake represents ﹤0.01% of the portfolio and ranks #3720 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

Squarepoint held 9,074 shares of First Tracks Biotherapeutics worth $322K as of Q3 2026.
First Tracks Biotherapeutics was a new Squarepoint position in Q3 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3720 holding.
89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.